Introduction {#s1}
============

Alzheimer\'s disease (AD) and Parkinson\'s disease (PD) are progressive, age-associated neurodegenerative disorders. Recent epidemiological studies revealed that around 50 million people worldwide are living with AD, and more than 10 million people above 60 years old with PD, respectively (Karlawish et al., [@B137]; Tysnes and Storstein, [@B260]). The prevalence of both diseases is increased in the highest age groups and the number will escalate rapidly the coming years (Karlawish et al., [@B137]; Tysnes and Storstein, [@B260]). While the clinical features are quite distinct between the two diseases, at the molecular level they are characterized by the misfolding, aggregation, and deposition of proteins in characteristic types of inclusions (Brion et al., [@B40]; Kosik et al., [@B156]; Iwai et al., [@B128]; Spillantini et al., [@B242]). Accumulation of aggregated tau is a hallmark of AD and related tauopathies and the accumulation of alpha-synuclein (aSyn) aggregates is the hallmark of PD and related synucleinopathies (Brion et al., [@B40], [@B41]; Kosik et al., [@B156]; Wood et al., [@B281]; Wischik et al., [@B280]; Spillantini et al., [@B242]; Baba et al., [@B16]; Bayer et al., [@B21]). aSyn and tau are abundant brain proteins, both known as intrinsically disordered proteins (IDPs) with prion-like properties, as they can misfold, seed, and spread the misfolded conformation to normal monomeric forms of each protein (Uversky and Fink, [@B269]; Eliezer, [@B83]; Bartels et al., [@B19]; Wu and Baum, [@B284]; Coelho-Cerqueira et al., [@B59]).

Different strains of aSyn and tau display different cell binding and penetration properties, resulting in transmission of pathology between cells (Clavaguera et al., [@B57]; Guo and Lee, [@B113]; Hansen et al., [@B115]; Angot et al., [@B9]; Kfoury et al., [@B140]; Masuda-Suzukake et al., [@B180]; Wu et al., [@B282]; Recasens and Dehay, [@B217]; Sanders et al., [@B229]; Grozdanov and Danzer, [@B109]). It is currently thought that distinct protein conformations account for differences in seeding potency. Interestingly, several studies revealed the accumulation of abnormal tau aggregates in numerous cases of aSyn deposition, and vice versa (Brion et al., [@B40]; Kosik et al., [@B156]). The coexistence of aSyn and tau aggregates suggests a strong cross-talk between tauopathies and synucleinopathies, and raises the hypothesis that cross-seeding might take place, thereby contributing to disease progression (Kosik et al., [@B156]; Spillantini et al., [@B242]; Cabrales Fontela et al., [@B48]). Furthermore, the interaction between aSyn and tau appear to promote the oligomerization and solubility of each other *in vitro* and *in vivo*, thereby disrupting cytoskeletal organization, impairing axonal transport, and compromising synaptic organization (Masliah et al., [@B179]; Giasson et al., [@B104]; Kotzbauer et al., [@B158]; Bellani et al., [@B23]; Cabrales Fontela et al., [@B48]; Sotiropoulos et al., [@B241]; Biswas and Kalil, [@B29]; Ordonez et al., [@B198]; Prots et al., [@B213]; Tuerde et al., [@B259]; Yuan et al., [@B290]). However, the exact molecular mechanisms involved in the cross-talk between the two proteins, and in the propagation of pathology, are still obscure. Here, we discuss the current knowledge about the mechanisms involved in transmission of both proteins, focusing on similarities and differences between the different spreading mechanisms.

aSyn Structure and Function {#s2}
===========================

Alpha-synuclein (aSyn) is a 14.5 kDa acidic protein of 140 amino acid residues, encoded by the *SNCA* gene (Chen et al., [@B55]), and is strongly implicated in PD. aSyn belongs to the synuclein family, together with beta- and gamma-synuclein.

aSyn was first isolated from the synaptic vesicles and nuclei of the electric organ of *Torpedo californica* (Maroteaux et al., [@B178]). In 1997, aSyn was identified as the major protein component of Lewy bodies (LBs) and Lewy neurites (LNs), the pathognomonic deposits in PD (Spillantini et al., [@B242]). In the same year, the first point mutation in the *SNCA* gene was associated with autosomal-dominant forms of PD, demonstrating the role of genetics in the disease (Polymeropoulos et al., [@B211]). Furthermore, the identification of families with duplications and triplications of the *SNCA* locus confirmed that increased levels of aSyn can cause disease (Singleton et al., [@B238]). These findings, along with a plethora of *in vitro* and *in vivo* studies, suggest that aSyn is a central player in a group of neurodegenerative disorders known as synucleinopathies.

aSyn is classified as an intrinsically disordered protein (IDP) as it lacks defined secondary structure (Uversky, [@B266], [@B267],[@B268]; Bernado et al., [@B26]; Breydo et al., [@B39]). Although the precise physiological function of aSyn is still unclear, several studies suggest that aSyn is involved in the regulation of synaptic membrane processes and in neurotransmitter release through interactions with members of the SNARE family (Tsigelny et al., [@B258]; Bellucci et al., [@B24]). Surprisingly, studies in aSyn knockout mice revealed that aSyn is not essential for synapse formation and cell survival (Bisaglia et al., [@B28]).

The primary sequence of aSyn can be divided in three distinct domains: the amino-terminal domain (N-terminal, residues 1--60), the central domain (residues 61--95) and the carboxy-terminal domain (C-terminal domain, residues 96--140). The N-terminal domain includes four repeats of the 11 amino acid alpha-helical lipid-binding motif (KTKEGV) ([Figure 1Ai](#F1){ref-type="fig"}, R1--4), enabling the formation of amphipathic α-helical structures upon interaction with lipid membranes (Jao et al., [@B131], [@B132]; Georgieva et al., [@B99]). The lipid composition of membranes is critical for aSyn binding. aSyn specifically prefers the binding in membranes characterized by high concentrations in cholesterol and sphingolipids, known also as lipid rafts. It seems that lipid rafts serve as a platform, which promotes aSyn binding and oligomerization (Davidson et al., [@B65]; Jo et al., [@B133]; Fortin et al., [@B90]; Zabrocki et al., [@B291]; Middleton and Rhoades, [@B184]; Fabelo et al., [@B87]; Hellstrand et al., [@B116]).

![Schematic illustration of aSyn and tau proteins. **(A)** aSyn is encoded by the *SNCA* gene. The primary sequence of aSyn can be divided in three distinct domains: the amino-terminal domain (N-terminal, residues 1--60), the central domain also known as NAC domain (residues 61--95), and the carboxy-terminal domain (C-terminal domain, residues 96--140). The N-terminal domain includes four repeats (R1--R4) of the 11 amino acid alpha-helical lipid-binding motif (KTKEGV). This region has propensity to form amphipathic α-helical structures upon interacting with lipid membranes. The NAC domain (non-amyloid-β component), contains three additional repeats (R5--R7) of the lipid-binding motif, is enriched in hydrophobic residues, leading to the formation of cylindrical β-sheets and amyloid-β fibrils. Both the N-terminal and NAC domain are characterized part of the membrane binding domain. The C-terminal domain is rich in acidic residues (15 acidic amino acids: 10 Glu and 5 Asp residues) and lacks defined secondary structure. **(B)** Tau is encoded by the *MAPT* gene. Alternative splicing of the *MAPT* gene results in six isoforms known as 2N/4R, 1N/4R, 0N/4R, 2N/3R, 1N/3R, and 0N/3R, depending on the presence or absence of exon 10 (4R or 3R) and on the numbers of amino-terminal inserts (0N, 1N, and 2N) encoded by exons 2 and 3. The primary sequence of the full-length human tau isoform can be divided in the N-terminal domain also known as projection domain, the central domain which is the microtubule binding domain (MTBD) and the C-terminal tail. The N-terminal consists of the acidic part encoded by exons 2 and 3 (E2-3) called inserts 1 and 2 (N1-2), followed by the proline-rich region (PRR). The MTBD in the longest isoform contains four repeats (R1-4). The region with the strongest propensity for microtubule polymerization is the oligopeptide "KVQIINKK" (residues 274--281), located in the sub-region between the R1--R2 repeats (red box). The C-terminal tail is enriched in positively charged residues. Notably, the region with the strongest propensity for microtubule binding is located in the sub-region between the R1--R2 repeats and, more specifically, is the oligopeptide "KVQIINKK" (residues 274--281), which is included only in the 4R tau isoform, providing a stronger binding affinity when compared to the 3R isoforms (Brandt and Lee, [@B36]; Goode and Feinstein, [@B108]; Sergeant et al., [@B236]).](fnmol-12-00107-g0001){#F1}

Importantly, all the known mutations associated with familial forms of PD are clustered within the N-terminal region of aSyn (Polymeropoulos et al., [@B211]; Kruger et al., [@B159]; Zarranz et al., [@B293]; Appel-Cresswell et al., [@B10]; Lesage et al., [@B164]; Proukakis et al., [@B214]; Pasanen et al., [@B203]), reinforcing the hypothesis that changes in the lipid binding domain may be linked to aSyn pathology. Interestingly, aSyn was reported to be acetylated at the N-terminus in cells, an essential modification that protects its native conformation against pathological aggregation (Iyer et al., [@B129]; Bu et al., [@B45]). The central domain, also known as NAC domain (non-amyloid-β component) ([Figure 1Ai](#F1){ref-type="fig"}), is enriched in hydrophobic residues and is involved in the pathologic aggregation of the protein due to conformational changes (El-Agnaf et al., [@B81]; Giasson et al., [@B105]; Bellucci et al., [@B25]). Interestingly, one phosphorylation site is present in the NAC domain---the S87 residue. S87 phosphorylation is increased in synucleinopathies, leading to inhibition of aSyn oligomerization which influences synuclein-membrane interactions (Paleologou et al., [@B201]). The carboxy-terminal domain (C-terminal domain) is characterized by a non-defined structure (Bisaglia et al., [@B28]) and incorporates most of the posttranslational modification sites (PTMs), including the most common phosphorylation at S129 (Fujiwara et al., [@B94]; Oueslati, [@B199]). The importance of phosphorylation is emphasized by a study showing that in DLB brains, approximately 90% of insoluble aSyn is phosphorylated at S129, compared with only 4% in soluble cytosolic aSyn (Anderson et al., [@B8]). This suggests the implication of phosphorylation in the aggregation propensity. These PTMs may act by modulating the structure, the physiological functions and the toxicity of aSyn. Furthermore, they can modulate protein-protein interactions, interaction with metal ions (Paik et al., [@B200]; Brown, [@B43]; Bisaglia et al., [@B28]), including Ca^2+^ binding (Nielsen et al., [@B194]), polyamine complexes binding, modulation of phospholipid-binding (Paleologou et al., [@B202]; Visanji et al., [@B272]), affecting the aggregation propensity of the protein. Moreover, the region plays a protective role against aggregation, due to the presence of all the five proline (Pro) residues of the protein (Meuvis et al., [@B183]). Changes in the charge or the hydrophobicity by residue substitution as well as deletion of the C-terminal lead to accelerated aggregation of aSyn *in vitro* (Hoyer et al., [@B123]). As mentioned above, aSyn has the ability to bind to acidic membranes. This binding is mediated by the amphipathic α-helix in the N-terminal domain. Under physiological conditions aSyn exists in a dynamic equilibrium between the unfolded cytosolic and the membrane--bound state (Burre et al., [@B47]). In contrast, under pathological conditions, aSyn adopts a β-sheet--rich amyloid conformation, which leads to the fibril formation and subsequently aSyn deposition into LBs (Pineda and Burre, [@B208]). Importantly, the α-helical part is responsible for the formation of the different types of oligomers, the species currently considered to be most toxic. However, the exact nature of those toxic species remains unknown, and is still unclear whether aggregation initiates from its lipid-bound part or from the unstructured cytosolic protein (Trexler and Rhoades, [@B257]; Chen et al., [@B54]; Ghosh et al., [@B102]; Gallea et al., [@B96]).

Tau Structure and Function {#s3}
==========================

Tau was first discovered associated with microtubules, together with other microtubule-associated proteins (Weingarten et al., [@B279]; Kolarova et al., [@B149]). For this reason, it was included in the family of microtubule-associated proteins (MAPs). There are six different isoforms of tau in the central nervous system, generated from the *MAPT* gene, as a result of alternative splicing. These isoforms range from 352 to 441 amino acids (Neve et al., [@B192]). Each of the six tau isoforms differs in their primary structure due to the content of three (3R) or four repeats (4R) of the microtubule binding domains in the C-terminal region, in combination with the presence or absence of one (N1) or two (N2) amino acid inserts in the N-terminal part of the protein. The six isoforms are known as 0N/3R (352 residues, 60 kDa), 1N/3R (381 residues, 64 kDa), 2N/3R (410 residues, 69 kDa), 0N/4R (383 residues, 64 kDa), 1N/4R (412 residues, 69 kDa), and 2N/4R (441 residues, 74 kDa) ([Figure 1 Bi](#F1){ref-type="fig"}), all showing higher apparent molecular masses than the predicted ones. Since the isoforms are differentially expressed in the brain during development, and stimulate microtubule assembly with different efficiencies, possibly possess particular physiological roles and implicated at different biological activities (Utton et al., [@B265]; Stanford et al., [@B245]). The shortest isoform is also known as "fetal tau isoform" because it is expressed also in the fetal brain, while all of them are detected in the human adult brain (Kosik et al., [@B157]; Stanford et al., [@B245]).

Importantly, in neurodegenerative diseases such as AD and PD, modified proportions of the different tau isoforms have been observed (Bre and Karsenti, [@B38]; Avila et al., [@B14]). Tau stabilizes the polymerization of microtubules through the three or four MTBR repeats in case of the longest isoform (Drubin and Kirschner, [@B77]; Maccioni et al., [@B175]). Under physiological conditions, in mature neurons, all tau protein is likely to be microtubule bound (Ackmann et al., [@B4]), and it is considered a dipole protein since the two ends of the protein have opposite charges (Sergeant et al., [@B235]).

The primary sequence of tau consists of the N-terminal domain, half of which is enriched in acidic residues, followed by a proline-rich region and the positively charged C-terminal tail.

Tau, like aSyn, is an intrinsically disordered protein, since it contains regions without defined secondary structure that are inserted between very short β-sheets and α-helices ([Figure 1Bii](#F1){ref-type="fig"}). The protein can also undergo different types of PTMs like phosphorylation, ubiquitination, acetylation, glycation, methylation, truncation of the N- or C-terminal regions or nitration (Avila et al., [@B14]; Garcia-Sierra et al., [@B98]; Avila, [@B13]; Morris et al., [@B187]; Huang et al., [@B124]; Iqbal et al., [@B126]), that likely modulate its normal function and lead to pathological features. Notably, tau contains a high number of potential phosphorylation sites (80 serines/threonines and 5 tyrosines) (Grundke-Iqbal et al., [@B110]; Bancher et al., [@B17]; Wang and Mandelkow, [@B277]). Most of these sites are located within the proline-rich region in close proximity to the MTBR domains and in the C-terminal tail ([Figure 1Bi](#F1){ref-type="fig"}) (Buee et al., [@B46]; Sergeant et al., [@B235]). The phosphorylation state of the protein affects the secondary structure and, subsequently, regulates all the normal and abnormal functions like development, interaction with different protein partners such as microtubules, localization, aggregation, and spreading (Camero et al., [@B50]; Multhaup et al., [@B189]; Wang and Mandelkow, [@B277]). In principle, a normal and strictly controlled level of phosphorylation is required for the appropriate function of the protein, while the pathological state is characterized by hyperphosphorylation that leads the tau to lose its biological activity (Kopke et al., [@B151]).

The deposition of hyperphosphorylated tau in insoluble filaments in the brain is a pathological hallmark not only of AD but also of related neurodegenerative diseases, known as tauopathies, including frontotemporal dementias (FTD) like Pick\'s Disease and argyrophilic grain disease, progressive supranuclear palsy, and corticobasal degeneration (Grundke-Iqbal et al., [@B110]). Major differences between tauopathies are the deposition of different isoforms of tau (Rademakers et al., [@B216]) and the occurrence of different structures of tau aggregates (Gerson et al., [@B100]; Dujardin et al., [@B78]). In AD, all the six-tau isoforms are hyperphosphorylated and aggregated into paired helical filaments (PHF) (Grundke-Iqbal et al., [@B111],[@B110]). In Pick\'s disease 3R isoforms are predominant, and the arrangement of tau is different than that in inclusions found in AD (Falcon et al., [@B89]). On the other hand, in the other tauopathies only the 4R isoform is present in the filaments (Goedert, [@B106]). In AD brains, the abnormally hyperphosphorylated tau is presented in the cytosol inhibiting the assembly of tubulin and disrupting microtubules. Furthermore, as a result of self-assembly is accumulated into neurofibrillary deposits in neurons and glial cells (Iqbal et al., [@B127]). In sporadic and familial FTD, several mutations have been identified in the tau gene. Some of these mutations are thought to disrupt the normal binding of tau to tubulin resulting in pathological deposits of hyperphosphorylated tau (Rademakers et al., [@B216]), or makes tau more vulnerable to self-aggregation (S422E, ΔK280, R5L, P301L, and R406W) (Haase et al., [@B114]; van Swieten et al., [@B271]; Mutreja et al., [@B190]). As with aSyn, it is believed that in a variety of tauopathies, the most toxic species are oligomeric, but the controversy is still not fully resolved. These oligomeric species are non-fibrillar, multimeric, soluble forms of the protein (Haase et al., [@B114]; Ghag et al., [@B101]). Examples of tauopathies where oligomers have been proposed as the toxic species include AD, corticobasal degeneration, Pick\'s disease, and progressive supranuclear palsy (Maeda et al., [@B176]; Patterson et al., [@B204]; Gerson et al., [@B100]).

Prions and Prion-like Spreading of Pathology {#s4}
============================================

Prion diseases are infectious diseases that can be transmitted horizontally between individuals of the same or even different species (Costanzo and Zurzolo, [@B60]; Kizhakke et al., [@B146]). In these diseases, PrP^C^ misfolds and converts into the pathogenic form PrP^Sc^. PrP^Sc^ then acts as a template, converting endogenous PrP^C^ into additional PrP^Sc^, thereby spreading pathology in the brain (Brandner et al., [@B35]). Other proteins may manifest prion-like behavior. The prion-like behavior of amyloid-β has been broadly studied (Walker et al., [@B275]; Ruiz-Riquelme et al., [@B222]; Sarnataro, [@B230]). Alterations in amyloid-β conformation lead to aggregation and the formation of plaques, and it has been reported that amyloid-β can reach the brain form outside the CNS (Eisele et al., [@B80]).

The stable propagation of different misfolded protein conformations was established as a defining feature of the prion paradigm and of the prion-like spreading of pathology (Jucker and Walker, [@B135]). Importantly, both aSyn and tau appear to spread in a prion-like manner (Holmes et al., [@B119]). However, different structural features may affect the way they propagate. Each protein has a characteristic core that undergoes conformational changes and may lead to aggregation. In particular, these are the NAC region in aSyn and the MTBR (together with the final part of the poliproline region) domain in tau (El-Agnaf et al., [@B81]; Ackmann et al., [@B4]; Giasson et al., [@B105]). Differences in these regions may lead to differences in the aggregated species formed. Whether aSyn and tau spreading have an infectious nature like that of the prion protein remains unclear. In general, protein infectivity depends on several factors, such as irreversibility of misfolded protein assemblies, the efficiency by which precursor polypeptides are recruited into aggregates, the clearance of the aggregates, and the efficiency of the spreading of misfolded protein proteins (Brundin et al., [@B44]).

Spreading of aSyn Pathology
---------------------------

aSyn neuropathology typically progresses in a predictable manner throughout the brain. Post mortem analysis of human brains revealed progression of neuropathology in a series of stages (Braak et al., [@B33]). Initially, the lesions start in the olfactory bulb, anterior olfactory nucleus, and dorsal motor nucleus of the vagus (Ordonez et al., [@B198]) in what is considered the first stage. During the second stage, pathology spreads to the lower raphe nuclei, the magnocellular portions of the reticular formation and the locus coeruleus (Prots et al., [@B213]). In the third stage, the pathology reaches the midbrain, affecting fundamentally the substantia nigra pars compacta (Braak et al., [@B33]). Pathology spreads then to the cortex during the fourth stage. In this stage the mesocortex is affected whilst the neocortex is unaffected (Braak et al., [@B33],[@B34]). In the last two stages, pathology reaches the neocortex. Initially affecting the prefrontal neocortex and then moving to the premotor areas, the primary sensory areas and the primary motor field (Braak et al., [@B33]).

aSyn can cross the blood-brain barrier (Peelaerts et al., [@B206]) and was shown to reach the central nervous system (CNS) after gastrointestinal administration (Holmqvist et al., [@B121]). It has been found in the choroid plexus, where it may be produced by the choroid cells that participate in its transport between the blood and cerebrospinal fluid (Bellani et al., [@B23]).

Additional studies showed the spreading of aSyn from diseased to healthy tissue. Several PD patients underwent embryonic neuronal cell transplantation developed the disease years after the surgery. The postmortem analysis of the tissue showed signs of PD, including the presence of LB and LN, in the grafted tissue. Interestingly, in these studies, the presence of cytosolic aSyn phosphorylated at S129 was also shown (Kordower et al., [@B154]; Li et al., [@B166]).

These studies, together with the Braak staging hypothesis, were considered strong evidence in favor of the prion-like spreading of aSyn pathology in the brain (Olanow and Prusiner, [@B196]).

Following these findings, several new studies revealed that aSyn can propagate from host to grafted tissue (Desplats et al., [@B71]; Angot et al., [@B9]; Reyes et al., [@B219]). A different set of studies showed how the administration of brain lysates from multiple system atrophy (MSA) patients into TgM83 mice brain leads to transmission in a way that is reminiscent of the transmission of the prion protein in chimpanzee brains in a model of Kuru (Gajdusek et al., [@B95]; Watts et al., [@B278]). This process was proposed to happen through cell-to-cell transmission following not only cell connectivity, and may reach parts of the CNS away from the injection site (Luk et al., [@B171]). Furthermore, 9 months after the inoculation of pathological aSyn from sarkosyl-insoluble fractions from cortical brain tissue from MSA patients, aSyn aggregates were found in the side contralateral to the administration (Bernis et al., [@B27]). Interestingly, in all these experiments human material leads to disease in different species. The transmission among different species is one of the main characteristics of prion proteins. Another argument in favor of the prion-like behavior of aSyn is that, under certain conditions, aSyn can assemble aberrantly forming prion strains (Guo et al., [@B112]; Peelaerts et al., [@B206]). When aSyn fibrils are inoculated in Wistar rats they act as seeds imprinting their intrinsic structures, turning monomeric aSyn into fibrils. When aSyn ribbons were injected, endogenous aSyn in Wistar rats acquired this specific conformation (Breydo et al., [@B39]). Furthermore, when two different strains of aSyn pre formed fibrils were inoculated in mice, endogenous aSyn acquired the structure of the strain inoculated (Peelaerts et al., [@B206]). Also, assemblies such as fibrils and ribbons can cross the blood-brain barrier and reach the CNS after intravenous injection (Uversky, [@B268]).

Several mechanisms have been put forward to explain the spreading of aSyn between cells. These include membrane pores (Stockl et al., [@B246]), passive diffusion (Ahn et al., [@B6]; Grozdanov and Danzer, [@B109]), receptor mediated endocytosis (Mao et al., [@B177]), through exo- and endocytosis (Lee et al., [@B161]), exosomal transport (Emmanouilidou et al., [@B84]), tunneling nanotubes (Abounit et al., [@B1],[@B2]; Dieriks et al., [@B74]), and the possibility of transport through carrier proteins (Sung et al., [@B248]; Yang et al., [@B288]) ([Figure 2](#F2){ref-type="fig"}).

![Possible mechanisms associated with the cell-to-cell transmission of aSyn and tau. The release of tau and aSyn is thought to take place via different mechanisms: (1) aSyn oligomers may form pore-like structures that penetrate the plasma membrane. These structures may act as non-selective channels, leading to the release of aSyn. At the present moment, there is less evidence in support of such mechanism for tau; (2, 8) Direct penetration of the plasma membrane may lead to protein release through passive diffusion and, consequently, passive uptake from the extracellular space, a common mechanism for both proteins; (3) aSyn and tau monomers and oligomers may be released in exosomes/secretory vesicles; (4) transmission of aSyn and tau may also occur via tunneling nanotubes which are membrane bridges between the cells composed by F-actin; (5) another possibility is that aSyn interacts with a possible carrier protein, which mediates the transfer in the plasma membrane and subsequently the release---it is still not known if tau could be released in this manner; (6) the release of both proteins may also take place from dying cells and the uptake of aSyn and tau could be mediated by cell surface receptors; (7) Heparan sulfate proteoglycans (HSPGs) may facilitate the internalization of aSyn and tau. Both proteins (monomers or fibrils) bind HSPGs at the cell surface, and then get internalized; (9) both proteins may be taken up by endocytosis.](fnmol-12-00107-g0002){#F2}

aSyn is present in extracellular fluids, as it has been found in human plasma and cerebrospinal fluid and in medium from cultured human M17 neuroblastoma cell line (El-Agnaf et al., [@B82]). The release of aSyn has also been shown in other cell lines such as SH-SY5Y cells, H4, MES cells, and in primary neurons (Lee et al., [@B161]; Danzer et al., [@B64]; Yamada and Iwatsubo, [@B285]). In these cells, aSyn is released through a calcium-dependent non-conventional pathway. Treatment with compounds that interfere with the normal function of endosomes result to significant changes in the extracellular levels of aSyn. Thus, the release pathway of aSyn is dependent on the integrity of the endosomal compartment (Emmanouilidou et al., [@B84]; Alvarez-Erviti et al., [@B7]; Emmanouilidou and Vekrellis, [@B85]). Release can also happen through exosomes. Exosomes are vesicles of \<100 nm of diameter that facilitate intercellular communication transporting proteins or RNA (Jansen et al., [@B130]; Mutreja and Gamblin, [@B191]). They can be released through budding forming a small vesicle or formed inside the multivesicular body, which fuses then with the cell membrane releasing its vesicles into the extracellular space (Beaudoin and Grondin, [@B22]; Denzer et al., [@B70]; Rustom et al., [@B224]). Membrane carrier proteins like the secretory carrier membrane protein 5 can also participate in the release of aSyn through exosomes (Yang et al., [@B288]). These release processes can happen from either the cell soma or the synaptic button, as aSyn is also transmitted trans-synaptically (Danzer et al., [@B64]; Freundt et al., [@B92]; Yamada and Iwatsubo, [@B285]), in processes that may or may not require axon-dendrite contacts (Freundt et al., [@B92]). Interestingly, mutant forms of aSyn such as the H50Q and the G51D are more prone to be released via exosomes and other types of extracellular vesicles than the wild type protein (Falcon et al., [@B89]). In addition, aSyn can also reach the extracellular space, not only by active mechanisms, but also passively by leakage through damaged cell membranes or by cell impairments. This process can be exacerbated by aSyn itself, as its interactions and fibrillization may disrupt cell membrane integrity (Volles and Lansbury, [@B274]; Chaudhary et al., [@B52]).

Internalization can then happen through the aforementioned mechanisms. During pinocytosis, aSyn is internalized in a dynamin-dependent process which seems to be more relevant for monomeric than for aggregated aSyn (Hansen et al., [@B115]). Furthermore, the endocytic process of aSyn internalization is a dynamin-dependent process, but not clathrin-dependent (Uversky, [@B267]).

Tunneling nanotubes are F-actin containing membranous bridges that connect the cytoplasm of remote cells, first described in PC12 cells (Abounit and Zurzolo, [@B3]). Fibrillar aSyn can spread from cell to cell in a prion-like way through tunneling nanotubes by mechanisms such as intercellular trafficking of lysosomes (Abounit et al., [@B1]; Dieriks et al., [@B74]). This happens not only among neuronal cells, but also in pericytes and astrocytes (Dieriks et al., [@B74]; Rostami et al., [@B220]), and from one type of cell to another (Sun et al., [@B247]).

Changes in aggregation propensity like the ones mentioned above lead to changes in the internalization and clearance of aSyn (Lee et al., [@B162]).

It has been proposed that aSyn can cross the cell membrane through pore-like structures such as the β-barrel voltage-dependent anion channel (Hoogerheide et al., [@B122]). These pores can be formed by aSyn itself in its oligomeric form, as it crosses the cell membrane leading to the formation of octameric ring structures, being the mutant A53T more prone to do it (Ma et al., [@B173]). The formation of these pores by aSyn is related with its binding properties to membranes and lipid layers. The association with these membranes leads to changes in membrane conductance which result to changes in its pore activity formation (Tosatto et al., [@B255]). The association with membranes is dependent on the presence of the KTKEGV repeat motif (Jao et al., [@B131]). In fact, binding of aSyn to the cell membrane causes permeabilization of the cell membrane by decreasing the lipid order (Stockl et al., [@B246]). This process also facilitates passive diffusion of the protein. Passive diffusion is a mechanism that allows exclusively the internalization of monomers (Lee et al., [@B162]). It is noteworthy that changes in the amphipatic N-terminus lead to an altered binding of aSyn to membranes. This results in abnormal vesicle interactions and changes the conformation of the vesicles, affecting aSyn spreading (Taneva et al., [@B251]; Dettmer et al., [@B72]). Out of the three known membrane proteins described to interact with aSyn, only the LAG3 and PrP^C^ mediate in its internalization through endocytosis (Chen et al., [@B54]; Mao et al., [@B177]; De Cecco and Legname, [@B67]). Activation of N-Methyl-D-Aspartate receptor (NMDAR) leads to the clathrin-mediated internalization of the receptor (Chen et al., [@B53]). Interestingly, activation of PrPc receptor by extracellular aSyn oligomers also leads to the phosphorylation of Fyn kinase activating the NMDAR receptor in a process that is independent of pore formation and impairs hippocampal long term potentiation leading to cognitive impairment (Diogenes et al., [@B75]; Chen et al., [@B54]).

Spreading of Tau Pathology
--------------------------

Tau also progresses in a predictable manner throughout the CNS. In AD, tau starts its propagation in the transentorhinal region and progresses through the hippocampus, cortex and the superior temporal gyrus, finally reaching the neocortex (Uversky, [@B266]; Braak et al., [@B31]). Nonetheless, particularly in FTD cases with Pick\'s disease type of tau pathology, atrophy progression starts in the frontal lobe and the hippocampus, then the temporal lobe and the insula, and finally pathology reaches areas of the parietal lobe (Broe et al., [@B42]; Gallea et al., [@B96]).

In mice, tau isoforms 2N4R, 2N3R, and 0N4R were found to readily and bidirectionally cross the blood-brain barrier (Ghosh et al., [@B102]).

Tau propagates trans-synaptically, mostly based on connectivity and not on proximity (Ahmed et al., [@B5]). This propagation happens mostly through afferent connections (Iba et al., [@B125]) and is mediated by trans-synaptic mechanisms (Dujardin et al., [@B79]), where transmission was proposed to take place through exosomes (Wang et al., [@B276]). Although propagation happens mainly through afferent connections, small tau species can be transported anterogradely and retrogradely in neurons (Wu et al., [@B282]). In P301S transgenic mice, tau pre-formed fibrils lead to templated misfolding of tau in a prion-like manner along neuronal connections (Stancu et al., [@B244]). When injected into the brain, aggregated P301S tau present in brain homogenates from P301S mice induces the spreading of filamentous tau pathology in ALZ17 mice (Clavaguera et al., [@B57]). Interestingly, the P301S mutant spreads at least five times faster than the wild type (WT) tau (Kundel et al., [@B160]).

In normal conditions, purified human tau does not form protein assemblies (Crowther et al., [@B61]). Polyanionic substances, especially glycosaminoglycans such as heparin or heparan sulfate proteoglicans (HSPGs), promote tau aggregation, thereby accelerating the formation of amyloid tau fibrils (Montejo de Garcini et al., [@B186]; Friedhoff et al., [@B93]). All six tau isoforms are able to aggregate even though, *in vitro*, the 4R isoforms are more prone to aggregation than the 3R isoforms (Zhong et al., [@B294]). Once the protein forms assemblies, these can act as seeds for the generation of new assemblies, even when they are applied extracellularly, spreading subsequently to other cells (Goedert and Spillantini, [@B107]).

Tau spreads from cell to cell through several different putative mechanisms, similar to those proposed for aSyn (Guo and Lee, [@B113]; Tardivel et al., [@B252]; Katsinelos et al., [@B138]; Polanco et al., [@B209]) ([Figure 2](#F2){ref-type="fig"}). A mechanism that was proposed to be more frequent for tau than for aSyn, is the internalization of the protein via macropinocytosis (Lee et al., [@B162]; Holmes et al., [@B119]) ([Figure 2](#F2){ref-type="fig"}). Macropinocytosis is an endocytic process driven by actin and involves the formation of the macropinosome in response to the direct actions of cargo/receptor molecules that coordinate the activity and recruitment of specific effector molecules, and subsequently fuse with degradative compartments of the cell (Kirkham and Parton, [@B144]; Kerr and Teasdale, [@B139]). Different types of HSPGs have been described to facilitate cellular internalization of aSyn and tau *in vitro* and *in vivo* and blocking their expression diminishes the internalization of tau and aSyn monomer and aggregates (Holmes et al., [@B119]; Gerson et al., [@B100]; Dujardin et al., [@B78]). Oligomers and short fibrils which bind to membranes can be internalized through receptor-independent mechanisms. On the other hand, monomers, long fibrils, or long filaments, are more dependent on receptor-mediated mechanisms (Wu et al., [@B282]). Extracellular tau can also affect the accumulation of endogenous tau in a way that is dependent on the tau isoform found in the extracellular space. In addition, it has been shown that oligomeric 0N4R tau induces the accumulation of endogenous tau to a small extent, while oligomeric 0N3R, 1N3R, and 1N4R tau do not stimulate accumulation of intracellular tau (Swanson et al., [@B249]).

Detachment of tau from microtubules, e.g., due to hyperphosphorylation, increases the levels of free intracellular protein, which can then cross the membrane through translocation mechanisms (Katsinelos et al., [@B138]). Certain extracellular forms of tau, especially soluble forms composed mostly of monomers and small oligomers, appear to be cytotoxic through muscarinic receptor activation, involving the tissue non-specific alkaline phosphatase (Sebastian-Serrano et al., [@B234]). Extracellular tau, mainly truncated forms, can also contribute to synaptic dysfunction (Brandt et al., [@B37]; Sebastian-Serrano et al., [@B234]). In fact, at least 75% of tau in the synapse of AD patients is C-terminally truncated, and can be released from cortical synapses and affect its physiological role (Sokolow et al., [@B240]). Interestingly, these truncated forms have been reported to undergo truncation from the C-terminus to inner regions and have been linked to the pathogenesis of AD (Basurto-Islas et al., [@B20]; Garcia-Sierra et al., [@B98]). So far, two major sites of truncation have been studied, especially truncation at residues E391 and D421. Interestingly, the truncation at D421 is not only found in AD brains, but also in Pick\'s disease brains, where C-terminal truncated tau has been proposed to be the main isoform found in exosomes (Mena et al., [@B182]; Gamblin et al., [@B97]; Basurto-Islas et al., [@B20]; Mondragon-Rodriguez et al., [@B185]; Kanmert et al., [@B136]). Furthermore, overexpression of the projection domain of tau suppresses neuronal growth factor-induced neurite formation, contributing to synaptic dysfunction (Brandt et al., [@B37]).

Cell Models for Studying the Spreading of aSyn and Tau {#s5}
======================================================

The mechanisms by which aSyn and tau spread through the central nervous system are of utmost importance to understand the progression of PD and AD, respectively. To study these mechanisms, several cell models of aSyn and tau spreading have been used in the last years.

Different cell lines have been used to study specific mechanisms underlying the spreading of aSyn and tau pathology. For instance, the mouse neuroblastoma N2a cell line has been extensively used to study cell-to-cell spreading through exosomes (Wang et al., [@B276]). Other cell lines, such as the HEK293, SH-SY5Y, and B103, or primary neuronal cultures, were also used to study exosomal-mediated release, but less frequently (Alvarez-Erviti et al., [@B7]; Polanco et al., [@B210]; Ngolab et al., [@B193]). The cell-to-cell transmission through tunneling nanotubes has been studied in the cathecolaminergic CAD cell line (Abounit et al., [@B1]). The C17.2 neural precursor cell line was used to study macropinocytosis (Holmes et al., [@B119]) ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

###### 

Cell models used to study aSyn spreading.

  **Model**                                                                                                                                               **Mutation**   **Result**                                                                                                                                                                                                                  **References**
  ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  SH-SY5Y                                                                                                                                                 None           aSyn can be transferred from one cell to another via exosomes                                                                                                                                                               Alvarez-Erviti et al., [@B7]
  N2a; primary hippocampal neuron; N2aprnp^−/−^                                                                                                           None           Prp facilitates the accumulation and spreading of aSyn aggregates in N2a cells and primary hippocampal neurons                                                                                                              Aulic et al., [@B12]
  HEK293T                                                                                                                                                 None           Used to titer the viral vectors                                                                                                                                                                                             Azeredo da Silveira et al., [@B15]
  Primary cortical neurons; primary astrocytes; human Lewy body incubation                                                                                None           Quantification of aSyn uptake in neurons and astrocytes                                                                                                                                                                     Cavaliere et al., [@B51]
  SH-SY5Y; primary cortical neurons; mouse cortical NSCs; aSyn expression using recombinant AdV                                                           None           aSyn uptaken by cells; observed cell-to-cell propagation                                                                                                                                                                    Desplats et al., [@B71]
  SH-SY5Y                                                                                                                                                 None           Cell to cell transfer in a 3D human neuron-like cell model                                                                                                                                                                  Domert et al., [@B76]
  SH-SY5Y; Tet-off system                                                                                                                                 None           aSyn is secreted through an endosomal pathway                                                                                                                                                                               Emmanouilidou et al., [@B84]
  HEK293; SH-SY5Y; SKMe15: N2A/SKMe15 coculture; CM with aSyn oligos                                                                                      None           aSyn can transfer between cells and seed the assembly of soluble aSyn                                                                                                                                                       Hansen et al., [@B115]
  Primary oligodendrocites; MN9D; Oli-neu; OLN93                                                                                                          A53T           Oligodendrocytes, Oli-neu, and OLN-93 uptake aSyn. Uptake is inhibited when clathrin heavy chain is silenced                                                                                                                Kisos et al., [@B145]
  Primary cortical neurons; SH-SY5Y; KG1C; PC12                                                                                                           A30P; A53T     Incorporated aSyn oligomers form cytoplasmic inclusions                                                                                                                                                                     Konno et al., [@B150]
  SH-SY5Y                                                                                                                                                 None           aSyn is secreted through exocytosis                                                                                                                                                                                         Lee et al., [@B161]
  SH-SY5Y                                                                                                                                                 A30P; A53T     High level of expression                                                                                                                                                                                                    Lo Bianco et al., [@B168]
  Primary neurons; primary astrocytes; fibril administration                                                                                              None           Transfer from neurons to astrocytes                                                                                                                                                                                         Loria et al., [@B169]
  Primary neuron, microglial and astrocyte culture; COS-7; HeLa; HEK293FT; SH-SY5Y; PFF administration; PFF with biotin; aSyn-biotin PFF administration   LAG3^−/−^      Pathologic aSyn transmission and toxicity is initiated by binding to LAG3 and that neuron-to-neuron transmission of pathological aSyn involves the endocytosis of exogenous ASyn PFF by the engagement of LAG3 on neurons   Mao et al., [@B177]
  B103; human exosome incubation                                                                                                                          None           Exosomes internalized by endocytosis                                                                                                                                                                                        Ngolab et al., [@B193]
  HEK293; infected with MSA and PD samples                                                                                                                A53T           Samples from MSA patients could be transmitted to cultured HEK cells but not samples from PD                                                                                                                                Prusiner et al., [@B215]
  OLN-93                                                                                                                                                  None           Capture of monomers, oligomers and fibrils                                                                                                                                                                                  Reyes et al., [@B219]
  N2a; neuronal iPS; CM                                                                                                                                   None           Transfer from neuron to neuron                                                                                                                                                                                              Reyes et al., [@B218]
  HEK293; PC12                                                                                                                                            None           High level of expression                                                                                                                                                                                                    Yamada et al., [@B286]

*CM, conditioned media; MSA, Multiple System Atrophy; PFF, Pre-formed fibril*.

###### 

Cell models used to study tau spreading.

  **Model**                                                                                                                                                                                 **Mutation**                            **Result**                                                                                                                                                                                                             **References**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  CAD; HeLa; h tau fibrils administration                                                                                                                                                   None                                    Tau fibrils are internalized and appear inside tunneling nanotubes                                                                                                                                                     Abounit et al., [@B2]
  Rat primary neuronal cultures; V5-Tau-LV or eGFP-LVs treatment                                                                                                                            P301L                                   Cell-to-cell transfer of WT V5-Tau protein via axonal transport from the primary neurons; transferred species mainly in a dephosphorylated state                                                                       Dujardin et al., [@B79]
  HEK293T; HEK-TREx-293; h tau transfection; sarkosyl insoluble tau and total brain lysate from TgP301S mice administration                                                                 P301S                                   Native Tau aggregates enter Cells through the same mechanism as recombinant Tau aggregates, consistent with macropinocytosis                                                                                           Falcon et al., [@B88]
  QBI-293; human WT, P301L, T43, t40/deltaK280, T40/P301L, and T40/R406W transfection; myc-tau and K18 fibril administration                                                                P301L; deltaK280; R406W                 Spontaneous fibril uptake is mediated by endocytosis                                                                                                                                                                   Guo and Lee, [@B113]
  C17.2; HEK293; tau RD-CFP, tau RD-YFP, and FRET biosensor for tau; aSyn-488, Htt exon 1 (Q50) administration                                                                              P301L; V337M                            Tau fibrils enter cells via macropinocytosis; HSPGs are receptors for cell uptake of tau and α-synuclein                                                                                                               Holmes et al., [@B119]
  Mice primary neuronal cultures; HEK293T; liposome transduction of tau seeds; treatment with tau, synuclein and Htt(Q50) seeds; tau RD-CFP, tau RD-YFP, and FRET biosensor tau cell line   P301S                                   Seeding with tau seeds; interaction with synuclein                                                                                                                                                                     Holmes et al., [@B120]
  HEK293; tau RD-CFP, tau RD-YFP, and FRET biosensor for tau                                                                                                                                deltaK280; P301L; V337M; I227P; I308P   Repeat domain aggregates transfer between cells, induce aggregation and propagate misfolding between cells; transfer within cell medium                                                                                Kfoury et al., [@B140]
  M1C; NB2a/d1; pRcCMV and pcDNA/V5-DEST transfection                                                                                                                                       None                                    Tau exon 2 insert inhibits tau secretion                                                                                                                                                                               Kim et al., [@B141]
  Primary neuronal cultures; primary microglial cultures; primary astrocyte cultures; COS-7; HeLa; HEK293FT; SH-SY5Y; PFF administration; PFF with biotin; aSyn-biotin PFF administration   LAG3 -/-                                Tau PFF do not bind LAG3                                                                                                                                                                                               Mao et al., [@B177]
  HEK293; HEK293T; tau RD-CFP, tau RD-YFP, and FRET biosensor tau cell line                                                                                                                 P301L                                   Transfer of seeds through exosomes; P301L tau-containing exosome-like EVs carry tau seeds that are capable of inducing aggregation of endogenous tau after being taken up by recipient tau biosensor cells             Polanco et al., [@B210]
  Primary neuronal cultures; mCherry-CD9-10 and Dendra2-CD9-10 transfection; exosome administration                                                                                         P301L                                   Exchange of exosomes by interconnected neurons                                                                                                                                                                         Polanco et al., [@B209]
  Primary neuronal cultures                                                                                                                                                                 None                                    Stimulation in release by neuronal activity; probably through a pre-synaptic mechanism rather than by extrusion of exosomes                                                                                            Pooler et al., [@B212]
  HEK293; tau RD-YFP, aSyn-YFP, htt exon 1 (Q25)-YFP                                                                                                                                        P301S                                   Seeding dependent on beta-sheet structure; tau propagates different strains; propagates to naïve cells after lysate transduction                                                                                       Sanders et al., [@B229]
  SH-SY5Y; h 3R1N, 4R1N, and HA-4R1N tau transfection; h APP-695 wild-type (WT), F690P, KM670/671NL, V717F, V717G, and APP-C99 transfection; h tau fibrils administration                   F690P (for APP)                         Overexpressed APP on the cell surface associates with tau fibrils and accelerates intracellular tau aggregation; transient expression of APP may increase the activity of cellular endocytosis and metabolism of APP   Takahashi et al., [@B250]
  CAD; V5-hTau1N4R, mCherry-tubulin and GFP-actin LV infection                                                                                                                              None                                    Extracellular tau species activate the formation of TNTs; tau is transported through TNTs via actin                                                                                                                    Tardivel et al., [@B252]
  N2A; GFP-Tau, RFP-Tau, GFP-flotillin                                                                                                                                                      deltaK280                               Release of seeding prone tau through exosomes; mutants for FTDP more prone; synaptic contacts are required for exosome-mediated transmission of tau                                                                    Wang et al., [@B276]
  Mice primary neuronal cultures; HeLa; low MW aggregates administration                                                                                                                    MAPT^−/−^                               Tau aggregates are taken up in tau KO mice neurons; small tau aggregates internalized and anterogradely transported in neurons and non-neuronal cells                                                                  Wu et al., [@B282]
  Mice primary neuronal cultures; RD-P301S YFP inoculation                                                                                                                                  P301L; MAPT^−/−^:GFP                    Transfer through cell medium                                                                                                                                                                                           Wu et al., [@B283]

*h, human; KO, Knockout; APP, Amyloid precursor protein; FTDP, Frontotemporal Dementia; TNT, Tunneling nanotube; WT, wild type; MW, molecular weight*.

Animal Models for Studying the Spreading of aSyn and Tau {#s6}
========================================================

In recent years, animal models based in the administration of different forms of aSyn and tau in specific brain and peripheral areas have been used ([Table 3](#T3){ref-type="table"}). The use of animal models enables us to address specific aspects of the spreading of aSyn or tau pathology, in particular those related to neuronal connectivity, or to the spreading between different organs (Braak and Braak, [@B32]; Delacourte et al., [@B69]; Zaccai et al., [@B292]). For aSyn, both mice and rats have been extensively used (Hansen et al., [@B115]; Masuda-Suzukake et al., [@B180]; Holmqvist et al., [@B121]; Recasens and Dehay, [@B217]), while in the case of tau most studies employed mice (Dujardin et al., [@B79]).

###### 

Animal models used to study aSyn spreading.

  **Model**                                                                                **Site of injection**                                            **Material injected**                                                                        **Mutation**                 **Result**                                                                                                                                                                                             **References**
  ---------------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------
  Sprague-Dawley rats                                                                      Substantia nigra                                                 AAV2/6-haSyn, transplanted rat VM DAnergic neurons                                           None                         Propagation from host tissue to transplanted dopaminergic neurons                                                                                                                                      Angot et al., [@B9]
  Mice: Prnp^−/−^; prnp^+/+^                                                               Substantia nigra                                                 Recombinant aSyn fibrils                                                                     None                         Spreading of aSyn may be facilitated by PrP                                                                                                                                                            Aulic et al., [@B12]
  Wistar rats                                                                              Substantia nigra                                                 AAV2/6-CMV:-aSyn, -S129A-aSyn, -S129D-aSyn, -A30P-aSyn, -A30P-S129A-aSyn, -A30P-S129A-aSyn   S129A; S129D; A30P           S129A leads to the formation of smaller aggregates, S129D to larger                                                                                                                                    Azeredo da Silveira et al., [@B15]
  Tg(SNCA)1Nbm/J                                                                           Left striatum                                                    MSA and ILBD brain lysates inoculation Insoluble fraction of human cerebral cortices         aSyn^−/−^                    Transmission of aggregates to the contralateral side 9 months after inoculation                                                                                                                        Bernis et al., [@B27]
  Rats: Sprague-Dawley, Wistar, Lewis; mice: C57BL/6J, SAMP8, SAMR1 *Callithrix jacchus*   Substantia nigra (rodents)                                       AAV2/9-p.A53T-haSyn pAAV2-CMVie/hSyn-synA53T-WPRE-pA                                         A53T                         Spreading to striatum and throughout the whole mesencephalon in rats 16 weeks after surgery. Absence of spreading for phosphor-aSyn in rats and marmosets                                              Bourdenx et al., [@B30]
  Sprague-Dawley rats                                                                      Substantia nigra                                                 rAAV2/1-aSyn                                                                                 G2019S (LRRK2); h aSyn OX    Neurodegeneration in the contralateral side                                                                                                                                                            Daher et al., [@B63]
  Sprague-Dawley rats                                                                      Substantia nigra                                                 rAAV6-aSyn-WPRE, rAAV6-aSyn+WRPE, or rAAV-CBA-mutant aSyn                                    h aSyn OX                    Retrograde progression of neurodegeneration                                                                                                                                                            Decressac et al., [@B68]
  (Thy1)-hαSYN transgenic mice                                                             Hippocampus                                                      Lentiviral GFP, stem cells, MCNSC cells                                                      h aSyn                       Transmission of aSyn from host to grafted NSCs; Inclusion body formation via cell-to-cell transmission of aSyn                                                                                         Desplats et al., [@B71]
  *Callithrix jacchus*                                                                     Substantia nigra                                                 rAAV2/5-CBA-aSyn                                                                             A53T                         Presence of aggregates in the CP 1 year after transduction in the SN                                                                                                                                   Eslamboli et al., [@B86]
  (Thy1)-h\[A30P\]aSyn transgenic mice                                                     None                                                             None                                                                                         A30P                         Widespread presence of aSyn aggregates after 12 months                                                                                                                                                 Freichel et al., [@B91]
  Sprague-Dawley rats; WT C57BL/6J mice                                                    Right cortex                                                     Recombinant aSyn monomers, oligomers and fibrils                                             h aSyn                       aSyn can transfer between cells and seed the assembly of soluble aSyn                                                                                                                                  Hansen et al., [@B115]
  C57BL/6J mice; C57BL/6JOlaHsd mice                                                       Left vagus                                                       AAV2/6-aSyn, AAV2/6-GFP                                                                      KO of SNCA gene; h aSyn OX   Spreading from medulla oblongata to rostral brain regions                                                                                                                                              Helwig et al., [@B117]
  Sprague-Dawley rats                                                                      Intestine wall of the stomach and duodenum                       PD brain lysate, recombinant aSyn monomers, oligomers and fibrils                            None                         Spreading from stomach and duodenum to CNS                                                                                                                                                             Holmqvist et al., [@B121]
  BDF1 mice                                                                                Striatum                                                         DLB brain lysate sarkosyl soluble/ insoluble fractions                                       h aSyn OX                    Inoculation fractions of human LBD in mice leads to CNS pathology                                                                                                                                      Jones et al., [@B134]
  Sprague-Dawley rats                                                                      Right substantia nigra                                           rAAV-CBA-GFP, rAAV-CBA-aSyn, rAAV-CBA-μaSyn                                                  A53T                         Overexpression of wt or mutant aSyn induce a progressive neurodegenerative pathology in the nigrostriatal DA neurons                                                                                   Kirik et al., [@B143]
  *Callithrix jacchus*                                                                     Substantia nigra                                                 rAAV-CBA-aSyn, rAAV-CBA-μaSyn, rAAV-CBA-GFP                                                  h aSyn OX                    Spreading from medulla oblongata to rostral brain regions. Release do not enhance interneuronal hα-syn propagation                                                                                     Kirik et al., [@B142]
  A53T aSyn tg mice; Clathrin silencing                                                    None                                                             None                                                                                         A53T                         Oligodendrocytes, Oli-neu and OLN-93 uptake aSyn. Uptake is inhibited by silencing the expression of clathrin heavy chain                                                                              Kisos et al., [@B145]
  Sprague-Dawley rats                                                                      Substantia nigra                                                 AAV-pTR-UF12, AAV-GFP, and AAV-pSyn30                                                        A30P                         Accumulation of aSyn in SN after 12 months; presence of Lewy-like neurites in the SN and the striatum                                                                                                  Klein et al., [@B148]
  Sprague-Dawley rats                                                                      Substantia nigra                                                 AAV1/2-A53T, AAV1/2-GFP, AAV1/2-EV                                                           A53T                         Transmission to the striatum from the SN                                                                                                                                                               Koprich et al., [@B153]
  Cynomolgus macaque                                                                       Substantia nigra                                                 AAV1/2-A53T, AAV1/2-aSyn, AAV1/2-GFP, AAV1/2-WPRE-bGH-polyA                                  A53T; scrambled A53T         Age-dependent increase in the accumulation of A53T; higher levels and more widespread degeneration with A53T                                                                                           Koprich et al., [@B152]
  F344 rats                                                                                Striatum and ventral mesencephalon                               AAV6-aSyn, AAV6-GFP                                                                          None                         Fetal DA neurons grafted into the striatum of 6-OHDA lesioned rats can retrogradely transfer h aSyn from the host into the graft                                                                       Kordower et al., [@B155]
  Rats                                                                                     Right substantia nigra                                           VSV-G-A30P, VSV-G-A53T, VSV-G-HWT                                                            A30P; A53T; wt               Overexpression of wt or mutated h aSyn leads to dopamine neuronal cell death in rodents not only in the site of injection                                                                              Lo Bianco et al., [@B168]
  TgM83 transgenic mice                                                                    Somatosensory cortex and dorsal neostriatum                      M83 mice brain lysate and recombinant aSyn fibrils                                           A53T; aSyn^−/−^              Pathological aSyn propagated along major CNS pathways to regions far beyond injection sites                                                                                                            Luk et al., [@B171]
  Sprague-Dawley rats                                                                      Above the right substantia nigra                                 rAAV6-aSyn, rAAV6-GFP                                                                        None                         Development of degenerative changes in the nigrostriatal axons and terminals and DA release impairments                                                                                                Lundblad et al., [@B172]
  C57BL/6 mice; CD1 mice                                                                   Striatum                                                         Recombinant aSyn fibrils                                                                     A53T; LAG3 -/-               Pathologic aSyn transmission and toxicity initiated by binding to LAG3, endocytosis of exogenous aSyn PFFs by the engagement of LAG3 on neurons                                                        Mao et al., [@B177]
  C57BL/6J mice                                                                            Substanstia nigra                                                Recombinant aSyn monomers and fibrils                                                        None                         aSyn is deposited in neurons through a prion-like mechanism or by seed-dependent aggregation by crossing the species barrier                                                                           Masuda-Suzukake et al., [@B180]
  TgM83 transgenic mice                                                                    Intracerebral inoculation                                        M83 mice brain lysate                                                                        A53T; aSyn^−/−^              Data consistent with prion-like propagation of aSyn                                                                                                                                                    Mougenot et al., [@B188]
  WT C57BL/6J × DBA/2F1 mice                                                               Hippocampus                                                      DLB exosomes                                                                                 None                         Exosomes may play a role in aSyn pathogenesis, possibly through the seeding of toxic forms of aSyn                                                                                                     Ngolab et al., [@B193]
  C57BL/6 mice                                                                             Right substantia nigra                                           rAAV2/7-haSyn                                                                                A53T                         Progressive nigral dopaminergic neuron loss, presence of aSyn-rich inclusions in the surviving cell bodies                                                                                             Oliveras-Salva et al., [@B197]
  Wistar rats                                                                              Right substantia nigra and striatum                              A53T α-SYN rAAV2/7, recombinant aSyn monomers, oligomers and fibrils                         h aSyn OX                    aSyn crosses the blood brain barrier; propagation in a stain-dependent manner                                                                                                                          Peelaerts et al., [@B206]
  TgM83 transgenic mice                                                                    Right parietal lobe                                              PD and MSA brain lysate, M83 mice brain lysate                                               A53T                         Transmission of MSA prions requires Tg A53T aSyn mice. Unsuccessful transmit PD to TgM83+/-- mice                                                                                                      Prusiner et al., [@B215]
  Mice: WT C57BL/6J; C57BI6Sv129; *Macaca fascicularis*                                    Above the substantia nigra (mice) and motor striatum (monkeys)   PD brain lysate                                                                              aSyn^−/−^                    Whether injected into the striatum or the SNpc, LB-induced degeneration was detected earlier and more extensively at the level of striatal dopaminergic axon terminals rather than SNpc cell bodies.   Recasens and Dehay, [@B217]
  C57BL/6J mice; Sprague-Dawley rats                                                       Cortex                                                           Recombinant aSyn monomers, oligomers and fibrils                                             h aSyn OX                    Transfer from host brain to grafted oligodendrocytes; oligodendrocytes take up recombinant aSyn monomers and oligomers                                                                                 Reyes et al., [@B219]
  (Thy1)-h\[A30P\]aSyn transgenic mice                                                     None                                                             None                                                                                         A30P                         Nutritional factors can have a significant impact on α-synucleinopathy                                                                                                                                 Rotermund et al., [@B221]
  Sprague-Dawley rats                                                                      Intravagal                                                       AAV2/6-aSyn                                                                                  h aSyn OX                    Transfer to medulla oblongata from higher brain regions                                                                                                                                                Rusconi et al., [@B223]
  Mice: M20^+/+^; BL6C3HF1                                                                 Lateral to the lateral ventricles                                Recombinant Δ71-82 and full lenght aSyn fibrils                                              h aSyn OX                    Non-amyloidogenic Δ71-82 aSyn induce pathology. Amyloidogenic h aSyn shows limited induction of neuronal aSyn inclusions                                                                               Sacino et al., [@B225]
  Mice: M83^+/+^; M83^+/−−;^ M20^+/+^; C3H/C57BL6 n                                        Biceps femoris                                                   Recombinant Δ71-82 and full lenght aSyn fibrils                                              A53T; h aSyn OX              Hindlimb intramuscular injection of fibrillar aSyn lead to CNS inclusion pathology                                                                                                                     Sacino et al., [@B226]
  Thy-aSyn mice                                                                            Oral administration                                              PD gut microbiota                                                                            aSyn OX                      Microbiota are required for the motor and GI dysfunction, postnatal gut-brain signaling by microbial molecules impact neuroinflammation and αSyn aggregation                                           Sampson et al., [@B228]
  (Thy1)-h\[A30P\]aSyn transgenic mice                                                     None                                                             None                                                                                         A30P                         Pathological aSyn species can impair synaptic plasticity                                                                                                                                               Schell et al., [@B231]
  *Callithrix jacchus*                                                                     Caudate nucleus and putamen                                      Recombinant human and mouse aSyn monomers and fibrils                                        None                         Retrograde progression of neurodegeneration                                                                                                                                                            Shimozawa et al., [@B237]
  C57BL/6                                                                                  Substantia nigra                                                 rAAV GFP and rAAV aSym                                                                       h aSyn OX                    Slow disease progression that mimics human disease and allows for earlier points of characterization and/or intervention                                                                               St Martin et al., [@B243]
  Wistar rats                                                                              Left substantia nigra                                            AVV2: -aSyn, A56P-aSyn, -A30P, -A30P/A56P/A76P, -EGFP                                        A30P; A56P; A30P/A56P/A76P   Fibrillar and prefibrillar aSyn variants secreted from rat primary cortical neurons                                                                                                                    Taschenberger et al., [@B253]
  C57BL/6J × CBA/ca hybrid mice                                                            None                                                             None                                                                                         Truncated 120 aa             h aSyn120 under the control of the TH promoter led to the formation of pathological inclusions in SN and OB                                                                                            Tofaris et al., [@B254]
  Rats; mice                                                                               Substantia nigra                                                 AAV: -aSyn, -EGFP                                                                            Truncated 120 aa             Development of inclusions in axons                                                                                                                                                                     Tozzi et al., [@B256]
  Sprague-Dawley rats                                                                      Right substantia nigra                                           rAAV5-αsynΔ110+rAAV5-GFP, rAAV5-αsynFL+rAAV5-GFP, or rAAV5-αsynFL+rAAV5-αsynΔ110             Truncated 110 aa             Mixture of truncated and full length, lead to increased accumulation and pathological aSyn in the striatum                                                                                             Ulusoy et al., [@B261]
  Sprague-Dawley rats                                                                      Left vagus                                                       rAAV6: -aSyn, -GFP                                                                           h aSyn OX                    Spreading from medulla oblongata to rostral brain regions                                                                                                                                              Ulusoy et al., [@B264]
  Sprague-Dawley rats                                                                      Left vagus                                                       rAAV6: -aSyn, -GFP                                                                           h aSyn OX                    Spreading from medulla oblongata to rostral brain regions                                                                                                                                              Ulusoy et al., [@B262]
  Sprague-Dawley rats                                                                      Substantia nigra                                                 AAV: -aSyn, -EGFP                                                                            None                         DMV nerve has a role in the transmission of aSyn from the brain to peripheral tissues                                                                                                                  Ulusoy et al., [@B263]
  Wistar rats                                                                              Substantia nigra                                                 rAAV: 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8, and 2/9 eGFP                                           None                         High widespread transgene expression                                                                                                                                                                   Van der Perren et al., [@B270]
  TgM83 transgenic mice                                                                    Right parietal lobe                                              MSA brain lysate, M83 mice brain lysates                                                     A53T; GFAP-Luc               Lethality upon transmission to animals and similar transmission to that of kuru, CJD, and related diseases                                                                                             Watts et al., [@B278]
  Sprague-Dawley rats                                                                      Left substantia nigra                                            rAAV-aSyn, rAAV-EGFP                                                                         None                         Progressive dopaminergic cell loss and aggregation                                                                                                                                                     Yamada et al., [@B286]
  Mice; *Macaca fascicularis*                                                              Substantia nigra (rodents and monkeys)                           Lentiviral A53T and GFP                                                                      A53T                         Age-dependent increase in the accumulation of A53T; higher levels of degeneration in monkeys than in mice                                                                                              Yang et al., [@B287]
  1K and 3K mice                                                                           None                                                             None                                                                                         E35K, 346K, 361K             3K mutation causes shift from cytosolic to membrane associated aSyn                                                                                                                                    Nuber et al., [@B195]
  M83, M47, and haSyn mice                                                                 Hippocampus and cortex                                           Recombinant human, mouse A53T and E36K aSyn fibrils                                          A53T, E46K                   Spreading of inclusion pathology only in M83 mice after 4 months                                                                                                                                       Sacino et al., [@B227]

*OX, overexpressing; CP, Cerebral Palsy*.

Non-human primates have already been used to study the spreading of aSyn pathology (Kirik et al., [@B142]; Eslamboli et al., [@B86]; Shimozawa et al., [@B237]), but have not been reported thus far for the study of tau spreading. Interestingly, a lamprey model has been used to study the effects of several tau mutations in the progression of neurodegeneration (Lee et al., [@B163]).

Transgenic mice expressing mutant forms of aSyn, such as A53T and A30P, have also been used, and are proving useful for studying other synucleinopathies including MSA (Giasson et al., [@B103]; Prusiner et al., [@B215]). For tau, the rTg4510 mouse line, harboring the P301L mutation, has been widely used (Barghorn et al., [@B18]).

Additionally, injections of viral vectors have been also extensively used to induce aSyn and tau overexpression. In the case of aSyn, several studies reported the mimicking of relevant PD features, the progressive nature, and the spreading of pathology, in mice, rats, and non-human primates (Kirik et al., [@B143], [@B142]; St Martin et al., [@B243]; Low and Aebischer, [@B170]). In the case of tau there are also models based on the use of viral vectors (Klein et al., [@B147]), including models for the study of rapid tau propagation (Asai et al., [@B11]) ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}).

###### 

Animal models used to study tau spreading.

  **Animal model**                      **Site of injection**                       **Material injected**                                                                                                                                       **Mutation**                         **Result**                                                                                                                                                                                                                         **References**
  ------------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  C57BL/6J mice                         Left hippocampus                            Mice brain extract                                                                                                                                          P301S                                Spreading through connectivity                                                                                                                                                                                                     Ahmed et al., [@B5]
  PS19 tau mice; microglial depletion   Medial entorhinal cortex, dentate gyrus     AAV2/6-SYN1, AAV2/6-SYN1-GFP, AAV2/6-GFP. Exosomes from microglial culture, exosomes from mouse brain lysates                                               P301L                                Participation of microglia in the spreading of tau; mediation of exosomes                                                                                                                                                          Asai et al., [@B11]
  Wistar rats                           Striatum                                    lentiviral hTau46WT, hTauP301L and GFP                                                                                                                      P301L                                AT8 immunoreactivity extends from the CA1 (Cornus Ammonis area 1) to the cortex in rats injected with LV-hTau46WT, whereas it is restricted to the hippocampal formation in rats injected with LV-hTau46P301L, even 8 months p.i   Caillierez et al., [@B49]
  C57BL/6J mice; ALZ17 mice             Hippocampus and overlying cerebral cortex   Mice brain homogenate                                                                                                                                       P301S                                Transmission of hyperphosphorylated tau in mice transgenic for human wt tau                                                                                                                                                        Clavaguera et al., [@B57]
  ALZ17 mice; APP23 mice                Hippocampus and overlying cerebral cortex   AD, tangle only dementia, Pick\'s Disease, argyrophilic grain disease, progressive supranuclear palsy, and corticobasal degeneration human brain extracts   P301S; h APP                         Self-propagation of tau inclusions independently of other pathological mechanisms                                                                                                                                                  Clavaguera et al., [@B56]
  C57BL/6J mice                         Intraperitoneal                             P301S and WT mice brainstem homogenate                                                                                                                      P301S                                Tauopathies can be seeded in the brain by tau aggregates delivered peripherally                                                                                                                                                    Clavaguera et al., [@B58]
  rTG tau EC mice                       None                                        None                                                                                                                                                        P301L                                Spreading of the pathology to downstream connected neurons                                                                                                                                                                         de Calignon et al., [@B66]
  Wistar rats                           Striatum                                    lentiviral V5-hTau46WT, hTau46WT, hTauP301L, and eGFP                                                                                                       P301L                                Spreading of Tau throughout the brain 8 months after post-injection; transmission through connected areas; trans-synaptic transmission                                                                                             Dujardin et al., [@B79]
  C57BL/6J mice                         Cortex                                      FL-Tau-488 fibrils                                                                                                                                          None                                 Tau fibrils enter cells via macropinocytosis; HSPGs are receptors for cell uptake of tau and aSyn                                                                                                                                  Holmes et al., [@B119]
  B6C3 mice; C57BL/6J mice              None                                        None                                                                                                                                                        P301S                                Tau seeding activity detected at 1.5 months, before any changes in histopathology; hyperphosphorylated tau accumulation                                                                                                            Holmes et al., [@B120]
  PS19 tau mice                         Locus coeruleus                             Recombinant tau fibrils                                                                                                                                     P301S                                The pattern of spreading did not match neurofibrillary tangles staging in h AD brains, developed tau pathology more rapidly after tau PFF injections into the LC.                                                                  Iba et al., [@B125]
  Lamprey                               Hindbrain                                   WT htau23 and htau24 plasmids                                                                                                                               P301L; G272V; V337M; R406W           All mutations accelerate progression                                                                                                                                                                                               Lee et al., [@B163]
  Neuropsin-tTA-Tau                     None                                        None                                                                                                                                                        P301L                                Spreading from the entorhinal cortex                                                                                                                                                                                               Liu et al., [@B167]
  Tg tau P301L mice                     Hippocampus                                 Recombinant tau fibrils                                                                                                                                     P301L                                Single injection of tau PFFs in the hippocampus or frontal cortex of young tauP301L mice acts as a seed to induce spreading of tau pathology throughout the mouse brain; neuron loss in the hippocampus                            Peeraer et al., [@B207]
  rTg4510 mice                          None                                        None                                                                                                                                                        P301L                                Transfer of seeds through exosomes; P301L tau-containing exosome-like EVs carry tau seeds that are capable of inducing aggregation of endogenous tau after being taken up by recipient tau biosensor cells                         Polanco et al., [@B210]
  B6C3 mice                             Hippocampus                                 Mice brain homogenate                                                                                                                                       P301S; h 4R1N                        Spreading from the left hippocampus after 5 weeks to the entorhinal cortex, retrospenial cortex and contralateral hippocampus                                                                                                      Sanders et al., [@B229]
  rTg4510 mice                          Cerebral cortex                             Recombinant tau short filaments                                                                                                                             P301L                                Tau aggregates taken up in tau KO mice neurons; tau aggregates internalized and anterogradely transported between brain cells                                                                                                      Wu et al., [@B282]
  rTg4510 mice; neuropsin-tTA-Tau       Medial entorhinal cortex and hippocampus    AAV5 CamKII.hM3Dq-mCherry, AAV9/CamKIIa.hChR2-mCherry, AAV9/CamKIIa.hChR2-mCherry                                                                           P301L; h tau; KO                     Stimulation of release and spreading by increased neuronal activity                                                                                                                                                                Wu et al., [@B283]
  JNPL3; Tg4510 mice                    Intraperitoneal                             Pan-tau Abs DA9, and DA31, PHF-tau CP13, and RZ3 antibodies; and 1 conformation-specific antibody MC1                                                       P301L                                Tau detected in serum                                                                                                                                                                                                              d\'Abramo et al., [@B62]
  mice JNPL3                            Hippocampus                                 AAV5-scFv-MC1, AAV5-eGFP                                                                                                                                    P301L                                Diffusion to distant areas                                                                                                                                                                                                         Vitale et al., [@B273]
  P19 mice                              Right lateral ventricle                     Human antisense oligonucleotides                                                                                                                            P301S                                Decrease in human tau mRNA reverses tau seeding                                                                                                                                                                                    DeVos et al., [@B73]
  SHR24, SHR72 rats                     Motor cortex                                Sarkosyl insoluble SHR72 and SHR24 brain homogenate                                                                                                         Truncated aa 151-391 3R and 4R tau   Spreading only of the SHR72 4R tau variant                                                                                                                                                                                         Levarska et al., [@B165]
  SHR72 rats                            Hippocampus                                 AD brain insoluble fraction, human brain extract                                                                                                            Truncated aa 151-391 4R tau          Exogenous human AD tau was able to spread from the area of injection and induce tau pathology                                                                                                                                      Smolek et al., [@B239]

Conclusions {#s7}
===========

Tau and aSyn pathologies spread in a manner that is reminiscent of the process of prion spreading in prion diseases, whereby misfolded forms of the proteins can act as templates and induce the misfolding of normally structured proteins. The altered proteins can spread from cell to cell throughout the CNS, and possibly also between different organs through neuronal connections.

In contrast to prion diseases, in AD and PD there is still no definitive evidence for horizontal transmission of tau or aSyn pathologies, as these proteins have not been shown to be infectious. Additionally, the spreading of pathology in synucleinopathies and tauopathies seems to be slower than that observed in prion diseases, but the reason for this is still unknown (Yekhlef et al., [@B289]; Peden et al., [@B205]; Schofield et al., [@B232]; Desplats et al., [@B71]; Angot et al., [@B9]; Reyes et al., [@B219]; Mabbott, [@B174]).

The putative mechanisms involved in the spreading of both tau and aSyn are thought to be similar. One difference is that tau appears to have greater propensity to be internalized through macropinocytosis. Another difference is that, thus far, no putative direct receptors have been involved in mediating tau internalization, whereas for aSyn several putative "receptors" have been reported.

From an anatomical point of view, aSyn and tau appear to spread from and to different locations, in patterns that are relatively predictable (McCann et al., [@B181]; Hoenig et al., [@B118]; Schwarz et al., [@B233]).

In conclusion, through the use of different model systems, it is becoming evident that the spreading of aSyn and tau pathologies share similar mechanisms, and there is hope that a deeper understanding of those mechanisms may lead to the identification of novel targets for therapeutic intervention in various neurodegenerative diseases.
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